Actively Recruiting
Collection of Clinical Data and Biological Samples for Severe Drug-Induced Skin Reactions Including Stevens-Johnson and Lyell Syndromes
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2022-05-03
500
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting clinical data and biological samples from patients with severe skin reactions caused by drugs. These conditions include Stevens-Johnson syndrome, Lyell syndrome toxic epidermal necrolysis, acute generalized exanthematous pustulosis AGEP, drug reaction with eosinophilia and systemic symptoms DRESS, drug-induced immunoglobulin A IgA bullous dermatosis, generalized bullous fixed drug reactions, maculopapular exanthema, and erythema multiforme. The goal is to better understand the biological and genetic causes of these drug reactions through research. Participants will provide various samples beyond routine care, including a small skin biopsy 6 mm punch, blood samples 43 mL, blister fluid, oral and nasal mucous membrane swabs, skin swabs, and stool samples. These samples will be stored in a specialized biological resource platform to allow detailed immunological, biological, and genetic studies. This is an observational study without specific treatment interventions. During the study, patients will undergo collection of clinical information and the biological samples described. Researchers will monitor the implementation of this collection and use the data and samples to perform various laboratory studies to explore the mechanisms of adverse drug reactions affecting the skin. Participation involves consenting and providing samples as outlined, with no therapeutic procedures. The study began in September 2018 and is expected to continue until 2028.
CONDITIONS
Brief Title
Drug Reactions Sampling (COLLECTIONTOXIDERMIES)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged 18 years or older
- Diagnosis of severe cutaneous drug reaction such as AGEP, DRESS, SJS/TEN, generalized bullous fixed drug eruption, drug-induced IgA bullous dermatosis, maculopapular exanthema, or erythema multiforme
- Signed informed consent
- Affiliated with social security
You will not qualify if you...
- Patients under legal protection or guardianship
Research Team
S
Saskia Oro, MD
L
Laetitia Gregoire
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here